AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

NMTC · NASDAQ · Medical - Devices

NeuroOne Medical Technologies

Develops thin-film electrode and ablation systems for neurological diagnosis and treatment.

$1.68

After-hours close−0.11 (−6.41%)

At close$1.80(−9.34%)

Something off on this page? Send us feedback.

Profile

NeuroOne Medical Technologies CorporationNMTCHealth Care

Develops and commercializes thin-film electrode and ablation systems for neurological diagnosis and treatment. Its single Neuromodulation Products segment sells Evo electrodes and OneRF ablation systems, with revenue also linked to a Zimmer collaboration and distribution arrangement.

Develops and commercializes thin-film electrode and ablation systems for neurological diagnosis and treatment through a single Neuromodulation Products segment. Its commercial offerings include Evo Cortical and Evo sEEG electrodes, plus the OneRF Ablation System and OneRF TN Ablation System.

The platform centers on minimally invasive, high-definition electrodes for diagnostic and therapeutic neurological applications. Evo sEEG uses the same electrode for diagnostic and therapeutic applications, while the OneRF systems extend the portfolio into ablation.

Operations are shaped by FDA clearance requirements, third-party contract manufacturers and suppliers, license agreements, and the Zimmer collaboration and distribution arrangement.

Company facts

CEODave Rosa

ListedMay 26, 2021

ExchangeNASDAQ

HeadquartersEden Prairie, MN

CountryUnited States

Employees18

CIK0001500198

ISINUS64130M3088

Key statistics

Market cap$15.4M

EPS (ttm)−$0.9634

P/E (ttm)−1.84

ROE-126.4%

P/B4.07

P/S1.54

Dividend yield—

Beta0.84vs XLV 0.21

Year to date −64.9% · Average volume (30d) 532.8K

Analysts

Price target, next 12 months$5.00+182.5%Median of 4 analysts · vs the Aug 28 close

ConsensusBuy3 of 4 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $1.77

High$5.00+182.5%

Median$5.00+182.5%

Low$5.00+182.5%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 14, 2026	Maxim Group	Reiterate	Buy	$3	$5
Sep 9, 2025	Maxim Group	Target			$3

Earnings

EPS

Estimate−$0.21

Reported−$0.28−33.3%

Revenue

Estimate$2.0M

Reported$2.0M−0.4%

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 13, 2026Q3 FY26	−$0.21	−$0.28	−33.3%	$2.0M	$2.0M	−0.4%	+20.39%
May 12, 2026Q2 FY26	−$0.23	−$0.25	−10.3%	$2.6M	$2.4M	−7.2%	+2.73%
Feb 17, 2026Q1 FY26	−$0.24	−$0.18	+25.0%	$2.7M	$2.9M	+8.9%	+0.25%
Dec 17, 2025Q4 FY25	−$0.04	−$0.05	−25.0%	$2.5M	$2.7M	+9.9%	+7.23%

View details

Financial highlights

	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Revenue	$1.4M	$1.7M	$2.7M	$2.9M	$2.4M	$2.0M
Gross profit	$771.1K	$914.8K	$1.5M	$1.6M	$1.3M	$1.2M
Operating income	−$2.7M	−$1.9M	−$1.4M	−$1.7M	−$2.1M	−$2.4M
Net income	−$2.3M	−$1.5M	−$1.6M	−$1.4M	−$2.1M	−$2.0M
Diluted EPS	−$0.44	−$0.19	−$0.26	−$0.17	−$0.25	−$0.28
Gross margin	55.6%	53.9%	55.8%	54.2%	53.8%	59.9%
Operating margin	-193.3%	-111.2%	-50.0%	-59.0%	-87.9%	-122.9%

Fiscal years (4-quarter sums)FY21 $178.1K · FY22 $171.2K · FY23 $2.0M · FY24 $3.5M · FY25 $9.1M

Balance sheet, Jun 30, 2026Cash & short-term investments $2.0M · Total debt $73.3K · Total assets $6.2M · Shareholders' equity $3.8M

Dividends

No dividends on record.

Ownership

Institutions 23.49%2.04M sharesInsiders 6.36%553.2K sharesOther 70.15%6.11M shares

Shares outstanding 8.70M · Float 6.88M · 79.1% free float

A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Pratt Brian · 10 percent owner	1.09M	12.48%	Form 4	Jul 14, 2026
Bleichroeder LP	666.7K	7.66%	13F	Aug 13, 2026
Vanguard Capital Management LLC	352.8K	4.05%	13F	Aug 13, 2026
Bard Associates Inc	305.4K	3.51%	13F	Aug 12, 2026
Perkins Capital Management Inc	244.7K	2.81%	13F	Jul 24, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jun 30, 2026	Mark Christianson	officer: Market Development Director	−10,000	$3.18
Mar 30, 2026	Mark Christianson	officer: Business Development Director	−15,363	$0.7400
Mar 13, 2026	Mark Christianson	officer: Business Development Director	−100	$0.8000
Mar 12, 2026	Mark Christianson	officer: Business Development Director	−817	$0.8000
Mar 11, 2026	Mark Christianson	officer: Business Development Director	−2,109	$0.8000